Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study
Initiatives
-
Compared with multiple daily injections (MDI), sensor-augmented pump (SAP) insulin therapy may reduce glycemic variability and oxidative stress in type 1 diabetes in a glycosylated hemoglobin (A1C)-independent manner. The STAR 3 study compared SAP with MDI therapy for 1 year.
Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.
- Start Year
- 2012
- End Year
- 2012
- Funding
- J.B.B, Y.C.K., T.B., and S.N.D have received research sup-port from Medtronic, Inc. J.S. and J.B.W. are employees ofMedtronic, Inc
Design
- Study design
- Clinical trial cohort
Marker Paper
Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther. 2012;14(7):644-647. doi:10.1089/dia.2011.0294
PUBMED 22524549
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 496
- Number of participants with biosamples
Access
Availability of data and biosamples
Data | |
Biosamples | |
Other |
Timeline
Subjects with a 1 year prior Type 1 diabetes diagnosis
Subjects with a 1 year prior Type 1 diabetes diagnosis
Selection Criteria
- Newborns
- Twins
- Ethnic Origin
-
- Health Status
-
- Type 1 diabetes
Recruitment
- Sources of recruitment
-
- Specific population
Number of participants
- Number of participants
- 496
- Number of participants with biosamples
Data Collection Event
Compared with multiple daily injections (MDI), sensor-augmented pump (SAP) insulin therapy may reduce glycemic variability and oxidative stress in type 1 diabetes in a glycosylated hemoglobin (A1C)-independent manner.
- Start Date
-
2012
- End Date
-
2012
- Data sources
-
-
Smart sensors
- Sensor- augumented pump
-
Smart sensors